news roundup
Last month’s people and business news updates feature Almac Group, Clinerion, ERT, Inteliquent, MMS Holdings, Parexel, Pharmaseal, PPD, PrisymID, WuXi Biologics, and more.
Parexel has opened its new collaboration hub location in Cambridge, complementing its headquarter location in nearby Newton, Mass. The location was established with its Parexel Biotech business in mind, with its clinical development, product and pipeline optimizaiton and regulatory services for the smaller life sciences community.
|
|
|
advertisement
Transforming Regulatory Affairs: Sharing Industry Peer Perspectives
On Demand
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
Covance, the drug development business of LabCorp, has announced its cohesive hybrid and virtual decentralized clinical trials solution that integrates capabilities across the two entities. The offering offers integration with Covance central laboratories, LabCorp specialty diagnostic laboratories, direct-to-patient market access call centers, and a suite of technology solutions designed for faster recruitment, and to bring trials closer to the patient.
|
advertisement
A Movement in Diabetes: Using Time-in-Range
On Demand
|
Articles
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) explores the use of a ride-sharing service to reduce transportation barriers for research participation, with supporting data and lessons learned for others to consider.
The authors of this article contend that it is important for investigators and allied health professions who are involved in clinical studies to be trained on the latest GCP guideline and provides documentation that its GCP Refresher Workshop is effective in refreshing participants’ knowledge on GCP guideline.
|
|
|
|
advertisement
Advances in RBM Drive the Clinical Trial of the Future
Access an online resource with useful tools and practical information about advances in RBM. The site provides useful white papers, articles, webcasts, and more.
 Access all resources
|
Blog Posts
A late 2019 report from the European Union on the pharma industry finds though there is a substantial increase of R&D investment in the biotech & pharma sector over the last 10 years, it has been accompanied by a decline in the number of patents filed per year. The report also highlights particular weaknesses in the EU industry by comparison with its US counterparts in the number of established biotech companies.
While FDA did not set any records last year in approving new drugs and biologics for market, it did speed a number of important new therapies to patients, in continuing to demonstrate its flexibility and support for biomedical innovation. Based on its criteria, the Center for Drug Evaluation and Research (CDER) approved some 50 new molecular entities (NMEs) in 2019.
| |
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
